Although CLDN18.2 and CLDN6 are recognized as promising tumor-associated antigen (TAA) genes, CLDN6 is highly expressed in ovary and testicular germ cell tumors, and CLDN18.2 is highly expressed in pancreatic and stomach tumors (Fig. S9). This evidence concerns the gene CLDN6 and gastric neoplasm.